Skip to main content
SpringerLink
Log in

FDA and Clinical Trial Data Monitoring Committees

  • Chapter
Data Monitoring in Clinical Trials

Based on authors’ work at the Center for Biologics Evaluation and Research, Food and Drug Administration.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. U.S. Food and Drug Administration. 1988. Guideline for the Format and Content of the Clinical and Statistical Sections of an Application. Rockville, MD: FDA. http://www.fda.gov/cder/guidance/statnda.pdf.

    Google Scholar 

  2. Ellenberg SS, Geller N, Simon R, Yusuf S (eds.). 1993. Proceedings of “Practical Issues in Data Monitoring of Clinical Trials,” Bethesda, Maryland, USA, 27–28 January 1992. Stat Med 12:415–616.

    Google Scholar 

  3. O’Neill RT. 1993. Some FDA perspectives on data monitoring in clinical trials in drug development. Stat Med 12:601–608.

    Article  Google Scholar 

  4. O’Neill RT. 1993. A regulatory perspective on data monitoring and interim analysis. In Buncher CR, Tsay JY (eds.): Statistics in the Pharmaceutical Industry. Marcel Dekker, New York.

    Google Scholar 

  5. Title 21, US Code of Federal Regulations. Part 50.24

    Google Scholar 

  6. Ellenberg SS. 1997. Informed consent: Protection or obstacle? Some emerging issues. Control Clin Trials 18:628–636.

    Article  Google Scholar 

  7. US Food and Drug Administration. 1998. International Conference on Harmonisation: Guidance on Statistical Principles for Clinical Trials. http://www.fda.gov/cber/gdlns/ichclinical.pdf.

    Google Scholar 

  8. ICH E9 Expert Working Group 1999. ICH Harmonised Tripartite Guideline: Statistical principles for clinical trials. Stat Med 18:1905–1942.

    Google Scholar 

  9. US Food and Drug Administration. 2001. Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees. FDA, Rockville, MD. http://www.fda.gov/cber/gdlns/clindatmon.htm.

    Google Scholar 

  10. Title 21, US Code of Federal Regulations, Parts 314.500–314.560. http://straylight.law.cornell.edu/cfr/cfr.php?title=21&type=part&value=314

    Google Scholar 

  11. Murray JM, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. 1999. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 13:797–804.

    Article  Google Scholar 

  12. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. 1991. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324:429–436.

    Article  Google Scholar 

  13. Siegel JP. 2002. Biotechnology and clinical trials. J Infect Dis 185:S52–S57.

    Article  Google Scholar 

  14. Derkx B, Wittes J, McCloskey R. 1999. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis 28:770–777.

    Article  Google Scholar 

  15. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. 1994. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121:1–5.

    Google Scholar 

  16. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 1995. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1588.

    Article  Google Scholar 

  17. PRISMS Study Group. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504.

    Article  Google Scholar 

  18. Goodkin DE. 1998. Interferon ß therapy for multiple sclerosis. Lancet 352:1486–1500.

    Article  Google Scholar 

  19. U.S. Food and Drug Administration. 1998. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. http://www.fda.gov/cder/guidance/1397fnl.pdf

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

    Susan S. Ellenberg

  2. Centocor Research and Development, Inc., Malvern, Pennsylvania

    Jay P. Siegel

Authors
  1. Susan S. Ellenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jay P. Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biostatistics and Medical Informatics, University of Wisconsin Medical School, Madison, WI, 53972-4675, USA

    David L. DeMets

  2. Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA

    Curt D. Furberg

  3. Bethesda, MD, USA

    Lawrence M. Friedman

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Ellenberg, S.S., Siegel, J.P. (2006). FDA and Clinical Trial Data Monitoring Committees. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_3

Download citation

Publish with us

Policies and ethics

Search

Navigation